Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment

Figures & data

Table 1. Clinical characteristics of study patients.

Characteristics	Total patients (n = 81)	Patients without prophylactic hepatoprotective agents (n = 46)
Age (years)
Mean age	37.60 ± 17.23	39.03 ± 15.39
≤18yrs	15(18.52%)	5(10.87%)
19-64yrs	64(79.01%)	40(86.96%)
≥65yrs	2(2.47%)	1(2.17%)
Sex
male	32(39.51%)	18(39.13%)
female	49(60.49%)	28(60.87%)

Data is presented as mean ± SD or n (%).

Figure 1. (A) Elevated WBC values between initial treatment and the first liver impairment occurred; (B) elevated GGT level between initial treatment and the first liver impairment occurred.

Figure 2. (A) Elevated WBC values between initial treatment and the first liver impairment occurred; (B) elevated GGT level between initial treatment and the first liver impairment occurred.

Table 2. Analysis of correlations between variations in enzymes levels.

	ΔALT R P-value	ΔAST R P-value	ΔGGT R P-value
ΔALT	1	0.649** 0.000	0.220 0.143
ΔAST	0.649** 0.000	1	0.255 0.087
ΔGGT	0.220 0.143	0.255 0.087	1

**P < 0.01; ΔALT, ΔAST and ΔGGT, the changes of ALT, AST and GGT in two groups between the time of first liver impairment and initiation of ATO treatment.

Figure 3. Liver enzymes in all patients: liver enzymes’ variation tendency in all patients. Hepatoprotective agents were used in some patients when liver enzymes were abnormal during ATO treatment process. initiation, the initiation of ATO treatment; W1,one week after ATO treatment; W2, two weeks after ATO treatment; W3, three weeks after ATO treatment; W4, four weeks after ATO treatment; withdrawal, withdrawal of ATO treatment and the last biochemical parameters measurement during the treatment.

Figure 4. Liver enzymes in patients without hepatoprotective agents: liver enzymes’ variation tendency in patients whose ALT and AST level were normal during the treatment process, no matter GGT levels were abnormal or not; d0,before ATO treatment; W1,one week after ATO treatment; W2, two weeks after ATO treatment; W3, three weeks after ATO treatment; W4, four weeks after ATO treatment.